Clinical pharmacology study of anti-estrogen based on pharmacogenomics and pharmacokinetics for hormone-sensitive breast cancer patients (JBCRG-15)

Clinical pharmacology study of anti-estrogen based on pharmacogenomics and pharmacokinetics for hormone-sensitive breast cancer patients (JBCRG-15) - JBCRG-15 (PGx-PK based clinical pharmacology study of anti-estrogen)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002632

Enrollment

Registered

2009-11-01

Start date

2010-10-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

Toremifen 40mg PO Dose escaration to 120mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Histologycally proven breast cancer On tamoxifen Reduced tamoxifen activity Able to take toremifen at least 3 months ECOG PS 0~2 20 to 70years old Adequite organ function Written IC obtained

Exclusion criteria

Exclusion criteria: History of thromboembolism Clinically significant myoma uteri Requiring CYP3A4 inhibitor Clinically significant co-morbidity Pregnant or its posibility

Design outcomes

Primary

Measure	Time frame
Change in toremifen metabolite concentration between 40mg and 120mg	—

Countries

Japan

Contacts

Public ContactHiroshi Ishiguro

Kyoto University Hospital Outpatient Oncology Unit

hishimd@kuhp.kyoto-u.ac.jp075-751-4771

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026